Rapid diagnosis of Mycoplasma pneumoniae pneumonia is required for timely treatment with effective antibiotics; however, PCR-based methods are often too expensive and technologically intensive for general use in clinical practice. In this study, the efficacy of the loop-mediated isothermal amplification (LAMP) assay for diagnosis of M. pneumoniae pneumonia in clinical practice was prospectively evaluated. From July 2011 to March 2012, 531 children hospitalized for communityacquired pneumonia were enrolled. In all patients, throat swabs were obtained on admission for the detection of M. pneumoniae DNA, and paired serum samples were obtained to assay M. pneumoniae particle agglutination (PA) antibody titers. M. pneumoniae pneumonia was diagnosed by either a positive LAMP assay or an increase of 4-fold or greater in the PA titer. Overall, 271 children (51.0z of the patients with pneumonia) were diagnosed with M. pneumoniae pneumonia. Among these, 258 (95.2z) and 248 (91.5z) were identified by the LAMP assay and serological tests, respectively. When the results of serological tests were considered as standard, the sensitivity, specificity, and positive and negative predictive values of the LAMP assay were 94.8z, 91.9z, and 91.1z and 95.2z, respectively. The median duration of pharyngeal carriage, as measured by the LAMP assay, was 9.5 days. Thus, the LAMP assay is useful in the rapid diagnosis of M. pneumoniae pneumonia.
Mycoplasma pneumoniae is a common cause of community-acquired pneumonia in children and young adults (1, 2) . At present, several methods are available for the definitive diagnosis of M. pneumoniae infections, including culture, serology, and nucleic acid amplification techniques. Detection of M. pneumoniae by polymerase chain reaction (PCR) as a rapid, sensitive, and specific method has been reported by many authors (3) (4) (5) . The loop-mediated isothermal amplification (LAMP) assay, a novel nucleic acid amplification method, for the rapid detection of M. pneumoniae was recently developed, and it has been demonstrated to have nearly the same sensitivity and specificity for detecting M. pneumoniae as PCR (6) . In our 1-year prospective study conducted to compare the diagnostic value of serological tests with that of the LAMP assay, the LAMP assay was found to be useful for the rapid diagnosis of M. pneumoniae pneumonia in clinical practice (7) . However, that study included a relatively small number of patients and employed the complement fixation test, which is less sensitive compared with other serological tests (8) as a reference against the LAMP assay. Therefore, further studies based on larger series of patients and optimal serological tests are suggested. In the present study, efficacy of the LAMP assay for rapid diagnosis of M. pneumoniae pneumonia was prospectively evaluated and compared with that of the particle agglutination (PA) test in pediatric patients diagnosed with community-acquired pneumonia.
We assessed a total of 531 otherwise healthy children aged 0.1-16.0 years (median, 4.8 years) with pyrexia, cough, and abnormal chest X-ray findings who were diagnosed with pneumonia between July 2011 and March 2012 and admitted to the Konan Kosei Hospital, Aichi Prefecture, Japan. On admission, throat swabs were obtained from all patients for the detection of M. pneumoniae DNA. DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Valencia, Calif., USA), and LAMP reactions were conducted using Loopamp DNA amplification kit (Eiken Chemical, Tokyo, Japan), as described previously (6, 7) . The LAMP products were detected as turbidity using a Loopamp real-time turbidimeter (RT-160C; Eiken Chemical). Paired serum samples were obtained on admission and at discharge to measure PA antibody titers to M. pneumoniae. For the detection of other pathogens, bacterial cultures and viral detection kits were employed, as described previously (7) . M. pneumoniae was confirmed as the cause of pneumonia when M. pneumoniae DNA was detected using the LAMP assay or when an increase of 4-fold or greater was observed in the PA antibody titer of any subject. Subjects in whom the LAMP assay was positive for M. pneumoniae infection and antimycoplasma treatment 
º0.01 Interval between 2 serological tests (days) 1) 6 was started immediately after admission were invited to undergo a follow-up LAMP assay every 2-3 days until either consecutive samples were negative or sufficient improvements in the clinical manifestations were evident. The study design and purpose were approved by the institutional review board of Konan Kosei Hospital.
A detailed explanation of the study purpose and protocol was provided to all participants and/or their guardians, and written informed consent was obtained from each prior to enrollment. Statistical analysis was performed using chi-squared test, one-way analysis of variance, and the Tukey-Kramer test with StatView 5.0 (SAS Institute, Cary, N.C., USA). A P value of º0.05 was considered statistically significant. During this 9-month prospective study, 271 of the 531 patients (51z; 145 males and 126 females; median age, 6.9 years; range, 0.5-15.2 years) were diagnosed with M. pneumoniae pneumonia. Among this patient group, the median intervals between symptom (cough, fever) onset and admission were 5 days (range, 1-12 days) and 6 days (range, 1-21 days), respectively. The median leukocyte count and C-reactive protein levels were 7,000 cells/mL (range, 3,000-22,900/mL) and 1.8 mg/dL (range, 0.1-20.6 mg/dL), respectively. Coinfection with other microorganisms was observed in 28 (10.3z) patients (Streptococcus pyogenes, n ＝ 10; Haemophilus influenzae, n ＝ 6; Staphylococcus pneumoniae, n ＝ 5; respiratory syncytial virus, n ＝ 5; and influenza virus type A, n ＝ 2). Among the 271 patients with M. pneumoniae pneumonia, results of the LAMP assay were positive in 258 (95.2z), 248 (91.5z) of whom were diagnosed as positive by serological tests. The results of the LAMP assay and serological tests correlated well because the negative and positive results were in agreement in 260 (49.0 z) and 235 (44.3 z) patients, respectively (Table 1) . When serological tests were considered as standard, the sensitivity and specificity were 94.8z (235/248), 91.9z (260/283), respectively, while positive and negative predictive values of the LAMP assay were 91.1z (235/258) and 95.2z (260/273), respectively. A comparison of the clinical characteristics of patients infected with M. pneumoniae by diagnostic methods is shown in Table 2 . Children in whom M. pneumoniae was detected by LAMP alone were significantly younger than those in whom it was detected by serological tests. The duration of symptoms before performing the LAMP assay and intervals between the two serological tests were significantly shorter in patients with positive results by the LAMP alone compared with those positive results by both assays. The proportion of patients who received treatment for mycoplasma (i.e., macrolides, quinolones, and tetracyclines) before sampling for the LAMP assay was significantly lower in case of patients with positive LAMP results compared with that in case of patients with positive serological tests. The mean leukocyte counts on admission were significantly higher in patients with positive results by LAMP alone. No significant differences were observed for other clinical manifestations. Results from follow-up samples assessed by the LAMP assay were complete in 21 patients and incomplete in 4 in whom the disease resolved. A survival curve determined by Kaplan-Meier analysis for these 25 M. pneumoniaepositive cases, which were assessed by the LAMP assay pneumoniae. In the present study, the results showed good global agreement between the LAMP assay and serological tests (495/531, 93.2z) in pediatric patients with pneumonia, 271 (51z) of which were diagnosed with M. pneumoniae infections. These findings are in contrast to those of our previous study, in which we identified M. pneumoniae pneumonia in 12.5z of pneumonia patients (7) , which may be explained by the periodic epidemics of M. pneumoniae, because this study period was coincident with a major outbreak in Japan (9). In this series, 23 patients were M. pneumoniae-positive according to the LAMP assay but negative according to the serological tests. These patients were significantly younger and were examined earlier following symptom onset before the LAMP assay was performed. Several reports have demonstrated a weak or deferred antibody response to M. pneumoniae in young children or patients in the early stages of disease (2, 10, 11) . These results were in accordance with our results. Furthermore, the interval between paired serum sampling was significantly shorter in our patients; thus, more patients may be diagnosed using serological tests if paired serum samples are obtained at longer intervals. Daxboeck et al. (8) stated that transient asymptomatic carriage of M. pneumoniae resulted from the persistence of the pathogen after previous disease and from infections during incubation periods. Asymptomatic healthy children act as carriers of M. pneumoniae at a rate of 0z-2.2z (12) (13) (14) ; however, because the detection of M. pneumoniae DNA in throat swabs is not necessarily indicative of a causative role of the pneumonic pathogen, an infectious state is often difficult to distinguish from carriage during the acute phase. Given the high positive predictive value of the LAMP assay in this study, the use of antimycoplas-ma therapy in LAMP-positive cases diagnosed with pneumonia may be reasonable. However, a positive predictive value is dependent on the prevalence of M. pneumoniae pneumonia, which may not be high during non-epidemic periods.
In 13 patients, M. pneumoniae pneumonia was accurately diagnosed by serological tests; however, the results of the LAMP assay were negative. These falsenegative LAMP results may have been caused by the disappearance of potential causative organisms resulting from treatment with previous antibiotics or by inadequate sampling techniques. Morozumi et al. (1) reported that PCR positivity was significantly lower among patients who were susceptible to M. pneumoniae and received antibiotics than among those who did not receive antibiotics. Furthermore, the specimen type can affect the rate of M. pneumoniae DNA detection (10) . Throat swabs from the oropharynx were used because of the difficulty in obtaining specimens from other respiratory organs in pediatric patients. However, some previous reports have shown that sputum is better suited than other specimens, including throat swabs, for the detection of M. pneumoniae DNA (10, 15) . Thus, the diagnostic accuracy of the LAMP assay for the detection of M. pneumoniae pneumonia may be higher using sputum, if available. In the present study, the detection of M. pneumoniae DNA by the LAMP assay was possible for an average of 9 days after the start of antimycoplasma treatment, after which the detection rate gradually decreased, suggesting that timely collection of pharyngeal swab specimens is critical for successful diagnosis. A combination of the LAMP assay and serological tests may accordingly be optimal in patients for whom treatment was initiated prior to performance of the LAMP assay.
In conclusion, the LAMP assay is a rapid, highly sensitive, specific, and simple method for the identification of M. pneumoniae.
